

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 9 NOVEMBER 2023

POLL RESULTS OF THE EGM

Tianda Pharmaceuticals Limited (the “**Company**”) is pleased to announce the poll results in respect of the resolutions proposed at the extraordinary general meeting of the Company held on 9 November 2023 (the “**EGM**”) as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
1.	To approve, confirm and ratify the supplemental agreement dated 20 September 2023 between the Company and Shanghai Pharmaceuticals Holding Co., Ltd.* (上海醫藥集團股份有限公司) (“ SPH ”), in relation to, among other things, the proposed revision of annual cap for the year ending 31 December 2023 for the transactions contemplated under the framework agreement dated 9 April 2021 between the Company and SPH, and the change of the expiry date of the 2021 Framework Agreement.	1,427,200,624 (100%)	0 (0%)
2.	To approve, confirm and ratify the framework agreement dated 20 September 2023 between the Company and SPH in relation to the sales of various pharmaceutical products, Chinese medicine and healthcare products manufactured and supplied by the Company and its subsidiaries to SPH and its subsidiaries from 1 January 2024 to 31 December 2026 and the terms of and proposed annual caps in relation to the transactions contemplated thereunder.	1,427,200,624 (100%)	0 (0%)

Note: Please refer to the notice of EGM of the Company dated 19 October 2023 for the full text of the resolutions.

* For identification only

As more than 50% of the votes were cast in favour of each of the above ordinary resolutions, all the ordinary resolutions were duly passed.

As at the date of the EGM, the total number of issued and fully paid up shares of the Company was 2,150,041,884 shares. The total number of Shares entitling the Shareholders to attend and vote for or against the resolution proposed at the EGM was 1,869,524,160 Shares. SIIC Medical Science and Technology (Group) Limited and its associates together were interested in 280,517,724 Shares, representing approximately 13.05% of equity interest in Company as at the date of the EGM, were required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited to and they did, abstain from voting on the above ordinary resolutions. There was no Share entitling a Shareholder to attend and vote only against the resolutions proposed at the EGM.

The EGM was convened by the Board and chaired by Mr. FANG Wen Quan, the Chairman and Managing Director of the Company. All the Directors of the Company attended the EGM in person or by electronic means.

Tricor Secretaries Limited, the Hong Kong Share Registrar of the Company, acted as scrutineer for the poll at the EGM.

Shareholders may refer to the circular of the Company dated 19 October 2023 (the “**Circular**”) for details of the above resolutions proposed at the EGM. The Circular may be viewed and downloaded from the Company’s website at www.tiandapharma.com or the designated website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

For and on behalf of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 9 November 2023

As at the date of this announcement, the Executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the Non-executive Directors are Mr. ZHONG Tao and Mr. FENG Quanming; and the Independent Non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Dr. XIAN Yanfang.